MacroGenics (MGNX) News Today $3.25 -0.13 (-3.85%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 7 at 11:15 AM | prnewswire.comMacroGenics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action LawsuitSeptember 6 at 12:19 PM | globenewswire.comMacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial – Hagens BermanSeptember 6 at 5:45 AM | prnewswire.comContact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)September 6 at 2:01 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 6 at 1:59 AM | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by BrokeragesMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has earned a consensus recommendation of "Hold" from the ten ratings firms that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The aveSeptember 5 at 12:47 PM | globenewswire.comClass Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & KorsinskySeptember 5 at 5:45 AM | prnewswire.comInvestors who lost money on MacroGenics, Inc.(MGNX) should contact The Gross Law Firm about pending Class Action - MGNXSeptember 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNXSeptember 3, 2024 | globenewswire.comMGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 3, 2024 | prnewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 3, 2024 | prnewswire.comInvestors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNXSeptember 2, 2024 | prnewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud LawsuitSeptember 2, 2024 | globenewswire.comMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens BermanSeptember 2, 2024 | globenewswire.comMacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPSeptember 1, 2024 | prnewswire.comKessler Topaz Meltzer & Check, LLP Notifies MacroGenics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action LawsuitAugust 31, 2024 | globenewswire.comROSEN, A TOP-RANKED LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNXAugust 31, 2024 | prnewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenicsAugust 30, 2024 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Shares Bought by Panagora Asset Management Inc.Panagora Asset Management Inc. grew its position in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 60.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 741,490 shares of the biopharmaceutical company's stock after purchasing aAugust 30, 2024 | globenewswire.comMacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion.August 29, 2024 | globenewswire.comMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens BermanAugust 29, 2024 | prnewswire.comMacroGenics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights - MGNXAugust 28, 2024 | globenewswire.comMGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 28, 2024 | globenewswire.comLevi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 – MGNXAugust 28, 2024 | prnewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 27, 2024 | globenewswire.comMacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNXAugust 26, 2024 | globenewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNXAugust 26, 2024 | prnewswire.comMGNX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against MacroGenics, Inc.August 26, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNXAugust 26, 2024 | globenewswire.comMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens BermanAugust 26, 2024 | prnewswire.comShareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreAugust 25, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenicsAugust 25, 2024 | globenewswire.comMacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPAugust 24, 2024 | prnewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud LawsuitAugust 23, 2024 | globenewswire.comMGNX INVETOR ALERT: Kirby McInerney LLP Reminds MacroGenics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitAugust 23, 2024 | marketbeat.comEquities Analysts Issue Forecasts for MacroGenics, Inc.'s Q3 2024 Earnings (NASDAQ:MGNX)MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at HC Wainwright lowered their Q3 2024 EPS estimates for shares of MacroGenics in a research report issued to clients and investors on Wednesday, August 21st. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company wAugust 23, 2024 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. Lawsuit - MGNXAugust 22, 2024 | globenewswire.comMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens BermanAugust 22, 2024 | globenewswire.comMGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 22, 2024 | globenewswire.comMacroGenics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNXAugust 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)August 22, 2024 | markets.businessinsider.comMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens BermanAugust 22, 2024 | prnewswire.comSeptember 24, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGNXAugust 21, 2024 | globenewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNXAugust 21, 2024 | globenewswire.comThe Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 – MGNXAugust 21, 2024 | prnewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenicsAugust 21, 2024 | marketbeat.comMacroGenics' (MGNX) Neutral Rating Reiterated at HC WainwrightHC Wainwright restated a "neutral" rating and set a $4.00 target price on shares of MacroGenics in a report on Wednesday.August 20, 2024 | globenewswire.comRobbins LLP Reminds MacroGenics, Inc. (MGNXX) Investors of the Class Action Lawsuit and Pending Lead Plaintiff DeadlineAugust 20, 2024 | globenewswire.comMGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 20, 2024 | prnewswire.comKessler Topaz Meltzer & Check, LLP Reminds MGNX Investors of September 24, 2024 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact the FirmAugust 20, 2024 | stockhouse.comROSEN, A LEADING LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MGNX Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Kamala’s Dirty Election Move… Revealed (Ad)According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. MGNX Media Mentions By Week MGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼0.020.55▲Average Medical News Sentiment MGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼167▲MGNX Articles Average Week Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Repare Therapeutics News Puma Biotechnology News Phibro Animal Health News Tectonic Therapeutic News Cronos Group News Dianthus Therapeutics News 4D Molecular Therapeutics News Zymeworks News Pliant Therapeutics News Humacyte News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
